Cargando…

Targeting CD22 for the Treatment of B-Cell Malignancies

Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surface sialoglycoprotein uniquely present on B-cells a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Nikesh N, Sokol, Lubomir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275043/
https://www.ncbi.nlm.nih.gov/pubmed/34262884
http://dx.doi.org/10.2147/ITT.S288546